Prot #HZNP‐HZN‐825‐303: A Phase 2b Randomized, Double‐blind, Placebo‐controlled, Repeat‐dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN‐825 in Subjects with Idiopathic Pulmonary Fibrosis

Project: Research project

Project Details

StatusActive
Effective start/end date5/2/23 → 5/2/26

Funding

  • PPD Investigator Services, LLC (Prot #HZNP-HZN-825-303 // Prot #HZNP-HZN-825-303)
  • Horizon Therapeutics Ireland DAC (Prot #HZNP-HZN-825-303 // Prot #HZNP-HZN-825-303)